欢迎访问《现代生物医学进展》编辑部！

目的：系统评价氨溴索注射液对慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效及对患者血清炎症因子CRP 及TNF- α 的影响。方法：①按照诊断标准共纳入60 例患者，按入院或就诊的先后顺序随机分成氨溴索治疗组和对照组，每组30 例患者；另设30 名COPD 稳定期患者作为稳定期对照组。② 治疗前后抽取静脉血，待测CRP 及TNF-α 水平；③ 对照组患者仅给予抗菌药物及解痉平喘药物等常规治疗；治疗组患者给予常规治疗外，还给予盐酸氨溴索注射液30mg，每天分2 次静滴，10 天为1 疗程；④治疗1 疗程后观察临床疗效及血清炎症因子水平的变化。结果：① 两组患者在性别，年龄，病程，病情，合并疾病的分布等基线资料上无显著性差异，P>0.05；② AECOPD 患者机体炎症因子水平较COPD 稳定期患者显著升高，P<0.01；氨溴索治疗组无论在临床疗效抑或降低血清炎症因子水平方面均要优于对照组，P<0.05。结论：盐酸氨溴索注射液辅助治疗可显著降低AECOPD 患者血清炎症因子水平，提高临床疗效

英文摘要:

Objective: Systematic evaluation the clinical efficacy of Ambroxol injection on chronic acute exacerbation of obstructive pulmonary disease (AECOPD) and the effects to patient serum CRP and inflammatory cytokines TNF-α. Methods: 60 COPD patients were randomly divided into ambroxol treatment group and control group, each group contained 30 patients; besides, the other 30 stable COPD patients as stable group. Control patients only received antibiotics and antispasmodic drugs and other conventional asthma therapy; treatment group were given conventional treatment, but also given Ambroxol Injection 30mg, 2 times a day intravenously for 10 days as a course of treatment. Before and after treatment, the serum levels of CRP and TNF-α were measured. Results: The baseline information, age, disease duration, patient's condition, concomitant diseases hade no significant difference between the two groups, P> 0.05. Compared with stable COPD patients, the levels of inflammatory cytokine in AECOPD patients were significantly increased, P <0. 01. Ambroxol treatment could significantly improve the clinical efficacy and reduce of serum levels of inflammatory cytokines, compared with control group, P<0.05. Conclusion: Ambroxol treatment can significantly improve the clinical efficacy and reduction of serum levels of inflammatory cytokines.

查看全文查看/发表评论下载PDF阅读器

关闭